

MAINE PUBLIC HEALTH ALERT NETWORK SYSTEM



*Maine Department of Health and Human Services
Maine Center for Disease Control and Prevention (Maine CDC)
(Formerly Bureau of Health)
11 State House Station
Augusta, Maine 04333-0011
Phone 1-800-821-5821 / Fax 207-287-7443*

*****ADVISORY – Important Information*****

2010PHADV011

TO: All Hospital Contacts, All Long Term Care Facilities, All Home Health

FROM: Dora Anne Mills, M.D., M.P.H., Public Health Director
Stephen Sears, M.D., M.P.H., State Epidemiologist

SUBJECT: Healthcare Professionals Warned Not To Use Certain Intravenous Metronidazole, Ondansetron, and Ciprofloxacin Due To Potential Contamination

DATE: Thursday, June 3, 2010

TIME: 10:30am

PAGES: 3

PRIORITY: Medium

Confidentiality Notice: This message is intended for the exclusive use of the individual or entity identified above. It may contain information, which is privileged and/or confidential under both state and federal law. If you are not notified otherwise, any further dissemination, copying, or disclosure of the communication is strictly prohibited. If you have received this transmittal in error, please immediately notify us at 287-6551 and return the original transmission to us by mail at Key Bank Plaza, 6th Floor-286 Water Street. Augusta, ME 04333, without making a copy. Your cooperation in protecting confidential information is greatly appreciated.

Maine Center for Disease Control and Prevention (Maine CDC)
(Formerly Bureau of Health)

Healthcare Professionals Warned Not To Use Certain Intravenous Metronidazole, Ondansetron, and Ciprofloxacin Due To Potential Contamination

Summary

The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals not to use certain intravenous (IV) bags of metronidazole, ondansetron, and ciprofloxacin because of potential contamination. FDA has received reports of floating matter in IV bags manufactured by Claris Lifesciences Limited, in Ahmedabad, India. Microbiological analysis identified the matter in one of the bags as a *Cladosporium* mold. Molds of this type can cause infections in susceptible patients, such as immunocompromised individuals. At this time, FDA is not aware of any reports of injuries due to administration of these products. Affected products include any metronidazole, ondansetron, and ciprofloxacin manufactured by Claris Lifesciences Limited and sold under the following labels: Claris, Sagent Pharmaceuticals, Pfizer, West-Ward Pharmaceuticals.

Background

Metronidazole and ciprofloxacin are antibiotics used to treat a variety of infections. Ondansetron is an antiemetic used to treat nausea and vomiting associated with chemotherapy or surgery. A complaint of white matter in a bag of metronidazole was received, and subsequent microbiological analysis identified the matter as a *Cladosporium* mold. Molds of this type can cause infections in susceptible patients, such as immunocompromised individuals. Another complaint of white matter in a bag of ondansetron was received and that bag is currently under analysis. Foreign matter should not be present in a sterile injectable product.

Recommendations

While FDA is learning more about the situation, healthcare professionals should NOT use and should immediately remove from their pharmacy inventories any metronidazole, ondansetron, and ciprofloxacin intravenous bags sold under the following labels:

- **Claris**
- **Sagent Pharmaceuticals**
- **Pfizer**
- **West–Ward Pharmaceuticals**

Only metronidazole, ciprofloxacin, and ondansetron in IV bags sold under the Claris, Sagent, Pfizer, and West-Ward Pharmaceuticals labels are affected. Claris is initiating a recall of all lots of these products. These products were all manufactured on the same production line.

For patients who have received any one of these products, clinicians are advised to stop usage immediately and observe patients for any signs of new infection (e.g., fevers or chills). Clinicians are requested to report any suspected adverse events following use of these products to FDA's MedWatch

program at 1-800-332-1088 or www.fda.gov/medwatch. On May 17, 2010, FDA posted an announcement that Sagent Pharmaceuticals, Inc. had announced a voluntary recall of specific lots of metronidazole injection (see <http://www.fda.gov/Safety/Recalls/ucm212302.htm>). Today's HAN Advisory announces a recall initiated by Claris covering all lots of the three affected products (metronidazole, ciprofloxacin, and ondansetron) manufactured by Claris and sold under the labels Claris, Sagent, West-Ward, and Pfizer.

For More Information:

FDA intends to provide new information when it becomes available. Clinicians with additional questions may contact FDA at 1-888-463-6332 or druginfo@fda.hhs.gov

Additional information is available at: www.fda.gov